BD ONCLARITY HPV TEST, 192

The BD Onclarity™ HPV Assay is FDA-approved for extended genotyping, offering the flexibility you need to adapt to changing screening guidelines and evolving patient management guidance.

FDA approved for all three screening paradigms:

In the post-vaccination era the prevalence of high-risk genotypes may change making it crucial to identify high-risk genotypes individually.

• Extended genotyping supports risk stratification and persistence monitoring to guide patient management^1-5
• Genotypes 16 and 18 account for 70% of invasive cancer worldwide, but their prevalence is declining as vaccination rates increase.^6-9
• Genotypes 31,33,58 have a CIN3+ risk similar to genotype 18, but 51,35,39,68,56,59,66 have a much lower risk.^10-11